Photonz - producing high purity EPA from algal fermentation

The Product

Photonz fermentation product PNZ0901, is a drug substance comprising high purity eicosapentaenoic acid (EPA).

This product is produced using Photonz' proprietary algal fermentation technology which overcomes a number of obstacles previously encountered in continuous fermentation of microalgae.

Compared with existing methods of production the Photonz method has several significant advantages. It is; sustainable; secure; traceable; consistent; scaleable and animal-free.

Photonz owns or controls seven patent families covering fermentation and purification of microalgal EPA.

News

  • Photonz receives $2.9 million R+D Grant

    Posted on Mar. 28, 2011

    Awarded under the TechNZ programme, the grant will enable the biotech company to undertake work that will, when completed, allow it to commence commercial production of the omega-3 fatty acid eicosapentaenoic acid (EPA) from marine micro-algae....read more
  • Photonz successfully transfers process to industrial scale

    Posted on Nov. 21 2011

    Photonz Corporation has achieved a major milestone on the path to commercially manufacturing, by fermentation, the high-value omega-3 fatty acid, EPA...read more
  • Photonz signs with Novasep

    Posted on Sep. 21 2011

    Biotech company Photonz Corporation has entered into a development agreement with Novasep, a world-class provider of purification technology...read more
Site by Jet Creative Studio